Cargando…
The SARS-CoV ferret model in an infection–challenge study
Phase I human clinical studies involving therapeutics for emerging and biodefense pathogens with low incidence, such as the severe acute respiratory syndrome coronavirus (SARS-CoV), requires at a minimum preclinical evaluation of efficacy in two well-characterized and robust animal models. Thus, a f...
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Inc.
2008
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831213/ https://www.ncbi.nlm.nih.gov/pubmed/18234270 http://dx.doi.org/10.1016/j.virol.2007.12.032 |